Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma.
Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma.
复制标题
DOI：
--
复制
发表时间：
2010
影响因子：
2
通讯作者：
Hirohito Kobayashi;Yoshimasa Tanaka;H. Shimmura;N. Minato;K. Tanabe
中科院分区：
文献类型：
--
作者：
Hirohito Kobayashi;Yoshimasa Tanaka;H. Shimmura;N. Minato;K. Tanabe
背景：Gammadelta T细胞近年来在肿瘤免疫治疗的发展中引起了相当大的关注，并已设计出几种不同的方法并应用于临床试验。病例报告1例肾癌根治性肾切除术后肺转移患者接受了6个周期的过继免疫治疗，采用体外激活的自体Gammadelta T细胞，然后静脉滴注小剂量白介素2和唑来膦酸。完全缓解已维持2年，未作任何额外治疗。免疫学分析表明，在移植后4小时至1天期间，干扰素-γ水平很高，外周血伽玛德尔塔T细胞在移植后7天比基准值增加了10倍。未观察到严重不良反应。结论Gammadelta T细胞过继免疫治疗是一种安全有效的过继免疫治疗方法，有望成为晚期肾癌的一种治疗方法。
BACKGROUND gammadelta T-cells have recently attracted considerable attention in the development of novel cancer immunotherapy, and several different approaches have been designed and employed in clinical trials. CASE REPORT A patient with lung metastasis after radical nephrectomy for renal cell carcinoma had six cycles of adoptive immunotherapy using autologous in vitro-activated gammadelta T-cells followed by low-dose interleukin-2 and zoledronic acid intravenous infusion. Complete remission was achieved which has been maintained for 2 years without any additional treatment. Immunological analysis demonstrated a high level of interferon-gamma four hours through one day following the transfer and peripheral blood gammadelta T-cells increased 10-fold from the baseline value, 7 days after the transfer. No serious adverse events were observed. CONCLUSION Adoptive immunotherapy using gammadelta T-cells was shown here to be clinically beneficial and safe, and may become a therapeutic option for patients with advanced RCC.